These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 22196957

  • 1. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L, D'Arena G, Zini G, Cascavilla N.
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S, Fanin R.
    Clin Transplant; 2011 Apr; 25(2):308-16. PubMed ID: 20412098
    [Abstract] [Full Text] [Related]

  • 3. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R, Yang JY, Sun HQ, Jia H, Liao J, Shi YJ, Li G.
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(14):2679-88. PubMed ID: 26221900
    [Abstract] [Full Text] [Related]

  • 4. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A, Simeone E, Pipan C, Saglio G, Fanin R.
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S.
    Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
    [Abstract] [Full Text] [Related]

  • 6. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A, Gillis D, Lewis I.
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [Abstract] [Full Text] [Related]

  • 7. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [Abstract] [Full Text] [Related]

  • 8. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J, Hajkova H, Haskovec C, Cechova H, Marinov I, Mikulenkova D, Markova J, Markova M, Vitek A, Valkova V.
    Neoplasma; 2013 Jun; 60(1):74-82. PubMed ID: 23067220
    [Abstract] [Full Text] [Related]

  • 9. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D.
    J Clin Oncol; 2009 Nov 01; 27(31):5195-201. PubMed ID: 19752335
    [Abstract] [Full Text] [Related]

  • 10. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Aurén J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT.
    Eur J Haematol; 2008 Mar 01; 80(3):201-7. PubMed ID: 18081724
    [Abstract] [Full Text] [Related]

  • 11. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W, Schoch C, Haferlach T, Schnittger S.
    Crit Rev Oncol Hematol; 2005 Nov 01; 56(2):283-309. PubMed ID: 16213150
    [Abstract] [Full Text] [Related]

  • 12. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.
    Rossi G, Minervini MM, Melillo L, di Nardo F, de Waure C, Scalzulli PR, Perla G, Valente D, Sinisi N, Cascavilla N.
    Ann Hematol; 2014 Jul 01; 93(7):1149-57. PubMed ID: 24554303
    [Abstract] [Full Text] [Related]

  • 13. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
    Miyazaki T, Fujita H, Fujimaki K, Hosoyama T, Watanabe R, Tachibana T, Fujita A, Matsumoto K, Tanaka M, Koharazawa H, Taguchi J, Tomita N, Sakai R, Fujisawa S, Kanamori H, Ishigatsubo Y.
    Leuk Res; 2012 Aug 01; 36(8):998-1003. PubMed ID: 22551655
    [Abstract] [Full Text] [Related]

  • 14. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P.
    Br J Haematol; 2004 Jun 01; 125(5):590-600. PubMed ID: 15147374
    [Abstract] [Full Text] [Related]

  • 15. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L, López O, Martino R, Brunet S, Bellido M, Rubiol E, Sierra J, Nomdedéu JF.
    Haematologica; 2000 Jul 01; 85(7):704-10. PubMed ID: 10897122
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. WT1 monitoring in core binding factor AML: comparison with specific chimeric products.
    Lasa A, Carricondo M, Estivill C, Bussaglia E, Gich I, Brunet S, Aventin A, Sierra J, Nomdedéu JF.
    Leuk Res; 2009 Dec 01; 33(12):1643-9. PubMed ID: 19427034
    [Abstract] [Full Text] [Related]

  • 19. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S, Emi N, Mitani K, Oyashiki K, Kitamura K, Morishita T, Ogawa H, Komatsu N, Soma T, Tamaki T, Kosugi H, Ohnishi K, Mizoguchi H, Hiraoka A, Kodera Y, Ueda R, Morishima Y, Nakagawa M, Tobita T, Sugimoto K, Chiba S, Inoue N, Hamaguchi M, Koga D, Tamaki H, Naoe T, Sugiyama H, Takaku F.
    Rinsho Ketsueki; 2005 Dec 01; 46(12):1279-87. PubMed ID: 16447800
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.